Loading organizations...
§ Private Profile · San Francisco, CA, USA
Healthcare technology company operating a platform connecting rare disease patients with research, generating real-world evidence.
AllStripes has raised $67.0M across 3 funding rounds.
Key people at AllStripes.
AllStripes has raised $67.0M in total across 3 funding rounds.
AllStripes is a San Francisco, California-based healthcare technology company that operates a digital platform to generate real-world evidence for rare disease research by securely anonymizing patient medical records. The organization provides biopharmaceutical companies and life sciences researchers with regulatory-ready data insights to accelerate drug discovery and clinical development. Prior to its acquisition, the enterprise scaled to over 100 employees and secured approximately $74 million in total venture funding, which included a $50 million Series B financing round. The company received financial backing from prominent venture capital firms and corporate investors, including Lux Capital, Spark Capital, McKesson Ventures, and Novartis dRx Capital. In October 2023, the business was officially acquired by PicnicHealth to further advance evidence generation capabilities across the rare disease sector. AllStripes was founded in 2017 by Nancy Yu and Onno Faber.
Key people at AllStripes.
AllStripes has raised $67.0M in total across 3 funding rounds.
AllStripes's investors include Lux Capital, AirAngels, Bain Capital Ventures, Bond, C2 Investment, Coalition Operators, Coinbase Ventures, Dimension Capital, First Round Capital, Gaingels, Greylock, M13.
AllStripes is a healthcare technology company that builds a patient-facing platform enabling individuals with rare diseases to securely contribute de-identified medical records and participate in research from home, generating regulatory-ready evidence to accelerate drug development.[1][2][3] It serves patients, families, over 30 patient advocacy organizations across 40 conditions, and life sciences companies, solving the challenge of scarce real-world data for rare diseases—affecting 1 in 10 people, half of them children—by streamlining data collection, analysis, and sharing to power faster treatments.[1][3] The company, a public benefit corporation (PBC), has raised $50 million to launch 100 new research programs, expand globally, enhance automation, and grow its team of 75 employees based in San Francisco.[1][3]
AllStripes (formerly RDMD) was co-founded in 2017 by CEO Nancy Yu and Onno Faber, a technology developer diagnosed with neurofibromatosis type 2, who became frustrated by the slow, patient-excluding drug development process for rare diseases.[1][3] Faber's personal journey—"Patients can’t be bystanders in drug development"—sparked the idea for a platform empowering patients to contribute data remotely, while Yu brought leadership to build transparent, inclusive tools.[1][3] Early traction included partnerships with advocacy groups, supporting over 3,000 users, and recognition as a World Economic Forum Technology Pioneer for its FDA-ready evidence generation.[1][5] The zebra-inspired name "AllStripes" symbolizes unity across rare conditions.[3]
AllStripes rides the real-world evidence (RWE) trend in healthcare tech, where patient-generated data fills gaps in rare disease trials—conditions too small for traditional studies—amid rising demand for faster approvals from regulators like the FDA.[1][5] Timing aligns with post-pandemic shifts to remote, decentralized research and AI-driven data automation, amplified by global rare disease awareness (300M+ affected worldwide).[3] Market forces like biopharma's push for diverse datasets and advocacy-driven inclusivity favor it, influencing the ecosystem by standardizing rare disease data sharing and enabling studies like LC-FAOD Odyssey at INFORM 2021.[1][7] Its acquisition by PicnicHealth further scales this impact in longitudinal health data platforms.[7]
AllStripes is poised to dominate rare disease RWE with its $50M-fueled expansion into 100 programs, global reach, and tech upgrades, potentially unlocking treatments for underserved conditions.[1] Trends like AI-enhanced analytics, regulatory embrace of RWE, and decentralized trials will propel growth, especially as biopharma invests in precision medicine. Its influence may evolve through deeper PicnicHealth integration, shaping inclusive research norms and returning power to patients—the core mission sparked by Faber's diagnosis.[3][7]
AllStripes has raised $67.0M across 3 funding rounds. Most recently, it raised $50.0M Series B in August 2021.